NodThera, a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today announced that it has secured $55 million (£44 million) in a Series B financing. NodThera’s lead candidate, NT-0167, is being evaluated in a Phase 1 clinical trial in healthy volunteers.


NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.



https://www.nodthera.com/

Biotechnology

Philadelphia, Pennsylvania, United States

NodThera Announces Close of $55 Million Series B Financing

Description

Company Information

Related People

Funding Insights